Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) – Equities research analysts at Leerink Swann issued their Q2 2019 earnings per share estimates for shares of Neovasc in a report issued on Thursday, November 15th. Leerink Swann analyst D. Antalffy expects that the medical equipment provider will earn $0.01 per share for the quarter. Leerink Swann also issued estimates for Neovasc’s Q3 2019 earnings at $0.01 EPS.

Several other research firms have also issued reports on NVCN. ValuEngine upgraded Neovasc from a “hold” rating to a “buy” rating in a research report on Saturday, September 22nd. Zacks Investment Research lowered Neovasc from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th.

NVCN opened at $1.25 on Monday. Neovasc has a 1 year low of $1.22 and a 1 year high of $92.00. The company has a market cap of $27.44 million, a P/E ratio of -0.03 and a beta of 1.44.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Gagnon Advisors LLC grew its position in shares of Neovasc by 2,416.2% in the 2nd quarter. Gagnon Advisors LLC now owns 46,032,686 shares of the medical equipment provider’s stock worth $1,970,000 after buying an additional 44,203,204 shares during the last quarter. Gagnon Securities LLC grew its position in shares of Neovasc by 350.7% in the 2nd quarter. Gagnon Securities LLC now owns 19,120,325 shares of the medical equipment provider’s stock worth $818,000 after buying an additional 14,878,428 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Neovasc by 837.5% in the 2nd quarter. Renaissance Technologies LLC now owns 53,754,832 shares of the medical equipment provider’s stock worth $2,300,000 after buying an additional 48,020,900 shares during the last quarter. Finally, Capital Research Global Investors bought a new stake in shares of Neovasc in the 3rd quarter worth approximately $1,917,000.

Neovasc Company Profile

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.

Featured Story: Asset Allocation and Your Retirement

Earnings History and Estimates for Neovasc (NASDAQ:NVCN)

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.